Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;30(6):1755-1763.
doi: 10.1111/ene.15768. Epub 2023 Apr 3.

Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function

Marika Pane  1   2 , Giorgia Coratti  1   2 , Valeria A Sansone  3 , Sonia Messina  4 , Michela Catteruccia  5 , Claudio Bruno  6 , Maria Sframeli  4 , Emilio Albamonte  3 , Marina Pedemonte  6 , Noemi Brolatti  6 , Irene Mizzoni  5 , Adele D'Amico  5 , Chiara Bravetti  2 , Beatrice Berti  2 , Concetta Palermo  2 , Daniela Leone  2 , Francesca Salmin  3 , Roberto De Sanctis  2 , Maria Carmela Pera  1   2 , Marco Piastra  7 , Orazio Genovese  7 , Federica Ricci  8 , Ilaria Cavallina  8 , Riccardo Masson  9 , Riccardo Zanin  9 , Caterina Agosto  10 , Eleonora Salomon  10 , Irene Bruno  11 , Andrea Magnolato  11 , Enrico Bertini  5 , Francesco Danilo Tiziano  12 , Francesca Bovis  13 , Eugenio Mercuri  1   2 ; Italian EAP Working Group
Affiliations

Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function

Marika Pane et al. Eur J Neurol. 2023 Jun.

Abstract

Background: We report the 4-year follow-up in type I patients treated with nusinersen and the changes in motor, respiratory and bulbar function in relation to subtype, age and SMN2 copy number.

Methods: The study included SMA 1 patients with at least one assessment after 12, 24 and 48 months from the first dose of nusinersen. The assessments used were Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) and the Hammersmith Infant Neurological Examination (HINE-II).

Results: Forty-eight patients, with ages ranging from 7 days to 12 years (mean 3.3 years, SD 3.6 years) were included in the study. The CHOP INTEND and HINE-II scores significantly increased between baseline and 48 months (p < 0.001). When age at starting treatment subgroups (<210 days, <2 years, 2-4 years, 5-11 years, ≥12 years) were considered, the CHOP INTEND increased significantly in patients younger than 4 years at treatment, while the HINE-2 increased significantly in patients younger than 2 years at treatment. In a mixed-model analysis, age, nutritional and respiratory status were predictive of changes on both scales while SMN2 copy number and decimal classification were not.

Conclusions: Our results confirm the safety profile previously reported and support the durability of the efficacy of nusinersen at 4 years with an overall stability or mild improvement and no evidence of deterioration over a long period of time.

Keywords: long-term results; longitudinal study; motor function; nusinersen; spinal muscular atrophy.

PubMed Disclaimer

References

REFERENCES

    1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.
    1. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
    1. Darras BT, Masson R, Mazurkiewicz-Beldzinska M, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427-435.
    1. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834-841.
    1. Masson R, Mazurkiewicz-Bełdzińska, Rose K, Servais L, Xiong H, Darras BT. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21:1110-1119.

Publication types